Jörg Neermann, Ph.D., currently serves as the CEO of the privately held German biotech company Curexsys GmbH. Prior to this, he worked for more than fourteen years as a Partner at the life science-focused investment firm Life Sciences Partners (LSP). Prior to joining LSP, Dr. Neermann was Managing Director at DVC Deutsche Venture Capital, a venture capital and private equity division of Deutsche Bank, where he built and ran its healthcare investment franchise. Previously, he started his venture capital career with Atlas Venture as an associate and investment manager.
During his career, he led and completed more than 80 financing transactions and was intimately involved in more than 15 M&A transactions and IPOs with a total transaction volume exceeding a billion euros. Dr. Neermann has a strong scientific background and hands-on finance and investment expertise and has served on the boards of numerous private and public European biotech and life science companies. He is currently a non-executive director at the German biotech company Vivoryon Therapeutics N.V., and Idea AG, a private German company.
Dr. Neermann studied biotechnology at the Technical University of Brunswick, Germany, and the Massachusetts Institute of Technology in Cambridge, Mass., and holds a master’s degree and a Ph.D. in biotechnology from the Technical University in Brunswick, Germany. He also studied economics at the Technical University in Brunswick, Germany, and at Harvard Business School.
Dr. Neermann has been a member of Immunic’s Board since April 2019. He serves on the Audit Committee and the Nominating and Corporate Governance Committee.